Lexicon Pharmaceutical Inc. (LXRX) stock Surges After Hours. Here’s why?
On December 30, the company announced the submission of the NDA for Sotagliflozin for the treatment of heart failure in Type2 Diabetes patients. Following the news, Lexicon Pharmaceutical Inc. (LXRX) surged in the after hours. Consequently, the stock was trading at $4.44 apiece in the after hours. During the regular session, the stock saw a […]
Lexicon Pharmaceutical Inc. (LXRX) stock Surges After Hours. Here’s why? Read More »